A. Barczyk (Katowice, Poland), R. Gosens (Groningen, Netherlands), O. S. Usmani (London, United Kingdom), A. Mathioudakis (Liverpool, United Kingdom)
Are extra-fine particles from dry powder inhalers likely to improve lung deposition?
D. Gjaltema, P. Hagedoorn, H. W. Frijlink, A. H. de Boer (Groningen, Netherlands)
|   |
In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles
C. Van Holsbeke, J. Marshall, J. De Backer, W. Vos (Kontich, Belgium; Cambridge, United Kingdom)
| |
The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI)
C. Van Holsbeke, J. Marshall, J. De Backer, W. Vos (Kontich, Belgium; Cambridge, United Kingdom)
| |
Median mass aerodynamic diameter (MMAD) and fine particle fraction (FPF): Influence on lung deposition?
C. Van Holsbeke, J. Marshall, J. De Backer, W. Vos (Kontich, Belgium; Cambridge, United Kingdom)
| |
Extent of inhaled drug deposition at variable inhaler inclination angles and airway geometries: An in-vivo study from a novel computational fluid dynamics model
A. Kuttler, T. Dimke (Basel, Switzerland)
| |
Holding chamber (Spacer) - A potential harbor of pathogenic bacteria
A. Agrawal, G. Nair, A. Uppe, U. Baby (Navi Mumbai, India)
| |
Mometasone furoate delivered via the Breezhaler® and Twisthaler® devices in asthma
F. Kanniess, G. Hanf, M. Hosoe, A. M. Tanase, S. Vaidya, R. Banerjee, B. Hederer (Reinfeld, Berlin, Germany; Basel, Switzerland; Cambridge, United States Of America; Hyderabad, India)
| |
Side effects of the leukotriene receptor antagonists in asthmatic children
S. Bahceci Erdem, H. T. Nacaroglu, C. S. Unsal Karkiner, I. Gunay, D. Can (Izmir, Turkey)
| |
Cost-effectiveness of bronchial thermoplasty (BT) treatment relative to no BT treatment option for patients with severe asthma
M. S. Koh, S. Y. Ang, S. W. Lam, J. Zhang, H. V. Nguyen (Singapore, Singapore)
| |
Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study
K. R. Chapman, E. D. Bateman, P. Olsson, H. Chen, D. Banerji, R. Fogel (Ontario, Canada; Cape Town, South Africa; Basel, Switzerland; East Hanover, United States Of America)
| |
Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
D. Singh, A. D'Urzo, P. Jones, C. Serra, V. Mergel, C. Caracta, A. Leselbaum (Manchester, London, United Kingdom; Toronto, Canada; Barcelona, Spain; Jersey City, United States Of America)
| |
The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies
L. McGarvey, A. Morice, J. Smith, S. Birring, F. Chuecos, B. Seoane, D. Jarreta (Belfast, Cottingham, Manchester, London, United Kingdom; Barcelona, Spain)
| |
Effect of the once-daily long-acting bronchodilator combination umeclidinium/vilanterol (UMEC/VI) and bronchodilator monotherapy on dyspnoea as measured by the transitional dyspnoea index (TDI) in COPD
M. Decramer, A. Anzueto, N. Richard, S. Harris, C. Kalberg, A. Church (Leuven, Belgium; Research Triangle Park, United States Of America)
| |
Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies
R. Buhl, R. Abrahams, L. Bjermer, E. Derom, M. Flezar, J. Hébert, A. Veale, L. Groenke, A. Hamilton, K. Tetzlaff, L. Korducki, H. Huisman, S. Waitere-Wijker, L. McGarvey (Mainz, Ingelheim, Tübingen, Germany; Morgantown, Ridgefield, United States Of America; Lund, Sweden; Ghent, Belgium; Golnik, Slovenia; Québec, Burlington, Canada; Adelaide, Australia; Alkmaar, Netherlands; Belfast, United Kingdom)
| |
Safety of tiotropium in renally impaired patients
D. Tashkin, N. Metzdorf, C. Hallmann, M. Könen-Bergmann, K. Kupas, R. Dahl (Los Angeles, United States Of America; Ingelheim, Frankfurt, Germany; Odense, Denmark)
| |
Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses
P. Calverley, M. Könen-Bergmann, N. Metzdorf, S. Bell, J. Hohlfeld (Liverpool, Bracknell, United Kingdom; Biberach, Hannover, Germany)
| |
Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat®
R. Dahl, H. Schmidt, M. Könen-Bergmann, N. Metzdorf (Odense, Denmark; Ingelheim, Germany)
| |
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD
E. Marquez-Martin, F. Ortega Ruiz, E. Campano, C. De la Horra, J. M. Varela, E. Calderón (Seville, Spain)
| |
Inflammation in COPD patients before and after roflumilast treatment
M. I. Vargas-Rojas, H. Solleriro-Villavicencio, A. Ramírez-Venegas, R. Hernández-Zenteno, O. Pérez-Bautista, A. Ziga-Martinez, R. Quintana-Carrillo, F. Dueñas-Morales, R. Sansores-Martínez (Mexico, Mexico)
| |
Preference, satisfaction and critical errors with Genuair® and Breezhaler® in patients with COPD
H. Chrystyn, S. Pascual, J. Feimer, A. De Soyza, J. Sauleda Roig, J. Haughney, L. Padullés, B. Seoane, L. Rekeda, A. Ribera (Huddersfield, Newcastle upon Tyne, Glasgow, United Kingdom; Barcelona, Palma de Mallorca, Spain; Munich, Germany; , United States Of America)
| |